NeuroPace : November Investor Presentation

Investor Presentation

November 2023

Disclaimer

In addition to background and historical information, this presentation contains "forward-looking statements" based on NeuroPace's current expectations, estimates, forecasts and beliefs, including financial results for the third quarter ended September 30, 2023, information about NeuroPace's market opportunity, growth drivers and market penetration, commercial strategy, future pipeline, estimates of market opportunity and forecasts of market and revenue growth, indication and TAM expansion opportunities, performance, assumptions and expectations relative to the DIXI Medical partnership, clinical trial timelines, and the statements under the captions "Current Patient Population Focus," "Annual Core U.S. Market Opportunity, "Closing the Treatment Gap," "Expanded Patient Eligibility," "Increased Therapy Utilization," "Distribution of DIXI Stereo EEG Products Leads to Earlier Patient Engagement," "Strategy to Drive Long-Term Growth," and "Financial Performance" in the slides that follow. These forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Additional risks and uncertainties include those described more fully in the section titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 02, 2023, and its Quarterly Report for the quarter ended September 30, 2023 on Form 10-Q to be filed with the SEC, as well as any reports that it may file with the SEC in the future. Forward-looking statements contained in this presentation are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this presentation and should not be relied upon as predictions of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.

This presentation contains statistical data, estimates, and forecasts that are based on independent industry publications or other publicly available information, as well as other information based on NeuroPace's internal sources. While NeuroPace believes the industry and market data included in this presentation are reliable and are based on reasonable assumptions, these data involve many assumptions and limitations, and investors are cautioned not to give undue weight to these estimates. NeuroPace has not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products or services.

2

NEUROPACE MISSION

Transform the lives of people suffering from epilepsy

by reducing or eliminating the occurrence of debilitating seizures.

NeuroPace Investment Highlights

	>$55B annual core U.S. addressable market; $2B original market within
Large, underpenetrated market	Comprehensive Epilepsy Centers with additional upside from new site
	expansion opportunity
Unique technology	closed loop, brain-responsive neuromodulation system
Compelling clinical evidence	Differentiated outcomes that continue to improve over time
Operating execution	accelerating revenue growth and reduced cash burn
Healthy balance sheet	sufficient capital to continue executing on key priorities through least mid-2025
Future growth opportunities	center expansion approval and generalized epilepsy indication expansion

4

1U.S., Center for Disease Control, August 10, 2017; Chen, Z., et al., JAMA Neurology, 2018; Hauser, et al., 1993. Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935- 1984. Epilepsia 34, 453-458; DEFINITIVE HEALTHCARE CLAIMS DATA, https://patientfinder.defhc.com as of 12/31/20

Management Team

Joel Becker	Martha Morrell, MD	Rebecca Kuhn
Chief Executive Officer	Chief Medical Officer	Chief Financial Officer

Irina Ridley	Kelley Nicholas
Chief Legal Officer	Vice President, Sales

Previous Experience

5

Drug-Resistant Epilepsy (DRE) is a Devastating, Highly Undertreated Disease with Significant Unmet Need

Epilepsy is a disorder in which abnormal electrical activity in the brain causes seizures

4th most common neurological disorder in the U.S.1 ~$28B direct medical costs in the U.S.1 2-3X higher unemployment among epilepsy patients2

Drug therapy is unable to control seizures for 1 in 3 patients3,4

1Examining the Economic Impact and Implications of Epilepsy, AJMC, February 13, 2020. 2Epilepsy Across the Spectrum 12.4.26: https://www.ncbi.nlm.nih.gov/books/NBK100603/ 3U.S. Center for Disease Control, August 10, 2017. 4Chen, Z., et al., JAMA Neurology, 2017.

6

One Third of Epilepsy Patients are Drug Refractory

U.S. Prevalence

DIAGNOSIS & FIRST LINE TREATMENT

Patients diagnosed	Try multiple anti-epilepsy	~1 in 3 have drug-resistant
with epilepsy	drugs	epilepsy (DRE)

3.4M People in the U.S.1

1.2M People in the U.S.2

7

1U.S. Center for Disease Control, August 10, 2017. 2Chen, Z., et al., JAMA Neurology, 2018.

RNS System - Novel Therapy to Address Unmet Need

Brain-Responsive Neuromodulation System Provides Unique Window to the Brain

Monitors	Recognizes & Responds	Records
Brain activity Continuously	To patient-specific seizures patterns	Ongoing iEEG data for physicians to review

Epilepsy Treatment that is

•	Personalized	Physician Programmer
•	Targeted
•	Data-driven
	Implantable Device with nearly 11-year battery	Patient Remote Monitor	Patient Data Management System

8

RNS System Data

Allows Physicians to Actively Manage and Customize Ongoing Patient Care

Identify Seizure Triggers

Monitor Patient Progress

See Effects of Therapy Changes		Electrographic
		seizures

Therapy change		Reveal Seizure Cycles

Inform Future Surgeries

9

Impressive Seizure Reductions Improve Over Time

Median % Reduction in Seizures

	82%
75%			72%	73%	75%
67%	62%	63%	67%
53%	58%

44%

Original FDA Study Results:1,2

• Statistically greater seizure reduction than sham therapy at
  5 months
• 75% median seizure reduction at 9 years
• 28% of patients achieved > 6 months of seizure freedom

Real World & FDA

Post Approval Study

Results:

• 67% median seizure reduction at 1 year3,4
• 75% median seizure reduction @ 2 years4
• 82% median seizure reduction at 3+ years4
• ~1 in 3 patients with > 90% reduction in seizures4

Year 1

Year 2

Year 3

Year 4

Year 5

Year 6

Year 7

Year 8

Year 9

Improvements shown in:

Cognitive Function | Quality of Life | Mental Health | SUDEP

10

1 Morrell, M, et al. Neurology, 2011. 2 Nair, D, et al., Neurology, 2020 and Heck et al., Epilepsia , 2014. 3 Szaflarski, JP, et al., Presented at American Epilepsy Society, 2019. 4 Razavi, B, et al., Epilepsia, 2020.